The global market for single-cell expression quantitative trait locus (eQTL) clinical workflows is poised for significant growth, driven by increased investments in genomic analysis by healthcare and life sciences organizations. According to a report added to ResearchAndMarkets.com’s offerings, the market expanded from $1.82 billion in 2025 to $2.18 billion in 2026, reflecting a compound annual growth rate (CAGR) of 19.6%1. This growth is attributed to heightened genomics research funding, a rising demand for disease biomarker identification, and a shift from traditional bulk sequencing to advanced clinical workflows.
The market is projected to reach $4.51 billion by 2030, with a CAGR of 19.9%. Key factors contributing to this growth include the adoption of single-cell sequencing technologies, the integration of artificial intelligence in genomic data analysis, the expansion of personalized medicine programs, and the automation of sample and library preparation processes. Notable trends in the market include high-resolution gene expression mapping, automated workflow pipelines, and predictive biomarker discovery.
Precision medicine is a major driver of demand for single-cell eQTL clinical workflows. As complex and chronic diseases become more prevalent, there is an increasing need for treatment strategies that consider individual genetic and cellular characteristics. Single-cell eQTL workflows enable researchers and clinicians to analyze gene expression variation at the cellular level, identify patient-specific therapeutic targets, and translate genomic data into clinically relevant insights. These capabilities support more targeted treatment selection, enhance biomarker development, and strengthen clinical decision-making.
The commercial and clinical potential of this market is further demonstrated by the expansion of personalized treatments. For instance, the U.S. Food and Drug Administration approved 16 new personalized treatments for rare diseases in 2023, up from six in 20222. This underscores the growing role of genomic technologies in therapeutic development and increases demand for scalable single-cell analysis workflows.
Innovation in this field is focused on integrating whole-genome sequencing data with single-cell RNA sequencing and computational analysis. In January 2023, Singleron Biotechnologies introduced a single-cell eQTL analysis workflow within its sequencing service portfolio. This bioinformatics pipeline leverages single-cell RNA sequencing and whole-genome sequencing data to predict cell-type-specific eQTLs, supporting population studies that require coordinated laboratory and computational capabilities3.
Strategic acquisitions are also influencing the competitive landscape. In November 2025, QIAGEN N.V. acquired Parse Biosciences Inc. for approximately $225 million. This acquisition enhances QIAGEN’s sample technologies portfolio by incorporating scalable, instrument-free single-cell sequencing solutions, thereby strengthening its position in AI-enabled biological research and drug discovery4. Such acquisitions are crucial for companies looking to expand their capabilities and maintain a competitive edge in the rapidly evolving genomic analysis market.
Regionally, North America was the largest market for single-cell eQTL clinical workflows in 2025, supported by advanced genomics infrastructure and strong biotechnology investment. The Asia-Pacific region is expected to experience the fastest growth during the forecast period due to increased sequencing capacity, biomedical research, and healthcare investment. The market analysis encompasses regions such as Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, including countries like Australia, Brazil, Canada, China, France, Germany, India, Indonesia, Italy, Japan, Russia, South Korea, Spain, Taiwan, the United Kingdom, and the United States.
The report segments the market by workflow type, technology, application, and end-user. Workflow types include sample preparation, library preparation, sequencing, data analysis, and other workflow types. Technologies covered are RNA sequencing, microarray, and PCR-based methods. Applications include disease research, drug discovery and development, and personalized medicine. End-users range from hospitals and clinics to research institutes and pharmaceutical companies.
In terms of technological advancements, the integration of artificial intelligence into genomic data analysis is a significant trend. AI can enhance the accuracy and efficiency of data interpretation, allowing for more precise identification of eQTLs and their role in disease mechanisms. Additionally, the automation of sample and library preparation processes reduces the manual labor involved, increasing throughput and consistency in results. These advancements are vital for meeting the growing demand for personalized medicine and targeted therapies.
Footnotes:
- The global single-cell eQTL market grew significantly from 2025 to 2026. Source.
- The FDA’s approval of personalized treatments increased notably from 2022 to 2023. Source.
- Singleron Biotechnologies launched a new single-cell eQTL analysis workflow in 2023. Source.
- QIAGEN’s acquisition of Parse Biosciences in 2025 expanded its portfolio significantly. Source.
Featured Image: Megapixl @ Netrun78
